ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Development and Validation of Epigenetic Signature Predict Survival for Patients with Laryngeal Squamous Cell Carcinoma

Cui, Jie; Wang, Liping; Zhong, Waisheng; Chen, Zhen; Chen, Jie*; Yang, Hong*; Liu, Genglong*广州医学院; 南方医科大学; 海南医学院; 1
DNA and Cell Biology2021-2-1DOI: 10.1089/dna.2020.5789
15被引8阅读
引用收藏
分享

摘要

Establishing epigenetic signature to improve the accuracy of survival prediction and optimize therapeutic strategies for laryngeal squamous cell carcinoma (LSCC) by a genome-wide integrated analysis of methylation and the transcriptome. LSCC DNA methylation datasets and RNA sequencing datasets were acquired from the Cancer Genome Atlas (TCGA). MethylMix was applied to detect DNA methylation-driven genes (MDGs), which developed an epigenetic signature. The predictive accuracy and clinical value of the epigenetic signature were evaluated by receiver operating characteristic and decision curve analysis, and compared with tumor-node-metastasis (TNM) stage system. In addition, prognostic value of the epigenetic signature was validated by external Gene Expression Omnibus (GEO) database. According to five MDGs of epigenetic signature, the candidate small molecules for LSCC were screen out by the CMap database. A total of 88 DNA MDGs were identified, five of which (MAGEB2, SUSD1, ZNF382, ZNF418, and ZNF732) were chosen to construct an epigenetic signature. The epigenetic signature can effectively divide patients into high-risk and low-risk group, with the area under curve (AUC) of 0.8 (5-year overall survival [OS]) and AUC of 0.745 (3-year OS). Stratification analysis affirmed that the epigenetic signature was still a significant statistical prognostic model in subsets of patients with different clinical variables. Multivariate Cox regression analysis indicated that the efficacy of epigenetic signature appears independent of other clinicopathological characteristics. In terms of predictive capacity and clinical usefulness, the epigenetic signature was superior to traditional TNM stage. In addition, the epigenetic signature was confirmed in external LSCC cohorts from GEO. Finally, CMap matched the 10 most significant small molecules as promising therapeutic drugs to reverse the LSCC gene expression. An epigenetic signature, with five DNA MDGs, was identified and validated in LSCC patients by integrating multidimensional genomic data, which may offer novel research directions and prospects for individualized treatment of patients with LSCC.

学科与关键词

关键词
laryngeal squamous cell carcinomaDNA methylation-driven genesepigeneticspredictionoverall survival
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
DNA and Cell Biology
发表日期
2021-02-01
卷期
第 40 卷, 第 2 期
页码
247-264
DOI
10.1089/dna.2020.5789
语言
ENGLISH
期刊收录
NSL
期刊等级
4区
成果收录
SCIE

作者

  • C

    Cui, Jie (第一作者)

    guangzhou med univ

  • W

    Wang, Liping

    1 · hainan med univ

查看全部 7 位作者收起作者
  • Z

    Zhong, Waisheng

    hunan canc hosp

  • C

    Chen, Zhen

    1 · southern med univ

  • C

    Chen, Jie (通讯)

    hunan canc hosp

  • Y

    Yang, Hong (通讯)

    guangzhou med univ

  • L

    Liu, Genglong (通讯)

    guangzhou med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417